This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.
(November 2017) (Learn how and when to remove this template message)
|Methyltestosterone||Androgen; Anabolic steroid|
|Trade names||Covaryx, Essian, Estratest, Menogen, Syntest|
|Drug class||Estrogen; Androgen|
Esterified estrogens/methyltestosterone (EEs/MT), sold under brand names such as Covaryx, Eemt, Essian, Estratest, Menogen, and Syntest, is a hormonal preparation that combines esterified estrogens (EEs) with methyltestosterone (MT) in one tablet and is used in menopausal hormone therapy.
EEs/MT is sold in tablet form, with either 1.25 mg EEs/2.5 mg MT or 0.625 mg EEs/1.25 mg MT available.
EEs/MT was first marketed in the United States in 1965 by Reid-Provident Laboratories, which as 100% of Reid-Rowell, Inc. stock was acquired by the Belgian pharmaceutical company Solvay in 1986. There has been some controversy surrounding the drug in recent years as to its status with the U.S. Food and Drug Administration.
Solvay sponsored a clinical trial of EEs/MT in the United States to determine whether the product is superior to treatment with esterified estrogens tablets.
EEs/MT was supplied by Solvay. In March 2009 Solvay announced that, based on a variety of business factors, it would discontinue supplying Estratest and Estratest HS tablets, and would stop accepting orders for the product on March 31, 2009.